3种治疗急性单核细胞白血病化疗方案的成本-效果分析  

Cost - effectiveness Analysis of Three Anticancer Chemotherapeutic Schemes for Acute Mononuclear Leuk- emia

作　　者：刘晓婕[1] 陈亚平[1] 

机构地区：[1]首都医科大学附属北京朝阳医院,北京市100020

出　　处：《中国医院用药评价与分析》2002年第5期284-285,共2页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨不同化疗方案对急性单核细胞白血病(M5)产生的经济效果。方法:采用药物经济学的成本-效果分析法对HAE组、DAE组、MAE组3种治疗M5的化疗方案进行回顾性分析评价。结果:DAE组方案为最合理方案。结论:药物经济学在优化治疗方案,帮助临床医师在临床治疗决策过程中选择最佳治疗方案具有一定的实际意义。OBJECTIVE: To evaluate the economic effectiveness in different chemotherapeutic schemes for acute mononu-clear leukemia(M5) .METHODS: Using pharmacoeconomic cost - effectiveness analysis, three chemotherapy schemes for Ms were compared.RESULTS: Among three schemes, DAE scheme was the best one.CONCLUSION: The results show that par-macoeconomics plays an important role in optimizing therapeutic scheme,in helping the physician to choose the best therapeutic plan in making clinical decision.

关 键 词：药物经济学 成本-效果分析 急性单核细胞白血病 化学治疗 

分 类 号：R733.710.5[医药卫生—肿瘤]